Research and Responsible Use
Guidance for researchers, care organizations and users of Level 42 AI® health-information technology.
.
Frequently Asked Questions
Learn about research collaboration, responsible use, privacy, validation, training and regulatory considerations for Level 42 AI® technology.
Who can collaborate with Level 42 AI®?
The website invites clinical research collaboration. Healthcare
organizations, researchers and other suitable partners can
contact Level 42 AI® to discuss potential scope and feasibility.
What should a clinical research collaboration include?
A collaboration should define the research question, protocol,
participant protections, ethics review, data governance,
analysis plan, validation approach and publication or
intellectual-property terms before study activity begins.
How should health data be handled?
Health data should be managed under applicable privacy laws,
informed-consent requirements, contractual terms and secure
access controls. Only authorized people should access, use
or share the data.
How should results be interpreted?
Results should be interpreted in the context of the configured
system, the individual’s history, symptoms, other clinical
information and the validated use case. Qualified healthcare
professionals should make diagnosis and treatment decisions.
What training is needed to use Level 42 AI® technology?
Operators should complete the setup, placement, workflow,
quality-control and data-handling training supplied for their
deployment. Correct procedures are important for reliable
data collection and safe use.
Does the website make a guarantee of health outcomes?
No. The website describes technology goals and potential
monitoring applications. Performance, suitability and outcomes
depend on the product, validated use case, operating conditions
and clinical or research implementation.
Why is validation important for biosignature algorithms?
Validation evaluates whether an algorithm performs reliably
for its intended population, setting and purpose. Results from
one study or population should not automatically be assumed
to apply to another.
Who should define data ownership and permitted use?
The participating organizations should document data ownership,
access, retention, permitted secondary use and deletion
responsibilities in contracts, consent materials and research
protocols.
How should research findings be communicated?
Findings should clearly describe the study population, methods,
limitations and validation status. Exploratory results should
not be presented as established clinical performance.
Are regulatory requirements the same for every deployment?
No. Requirements can vary by product claims, intended use,
population, healthcare setting and country. Qualified legal,
regulatory and clinical reviewers should assess each proposed
deployment.
Want to learn more?
Speak with the Level 42 AI® team about research collaboration, data governance or responsible deployment.
